TGFbeta1 T29C polymorphism and cancer risk: a meta-analysis based on 40 case-control studies.
Bing-Bing Wei,Bo Xi,Ruoqi Wang,Jin-Ming Bai,Jun-Kai Chang,Yun-Yun Zhang,Raegan Yoneda,Jian-Tang Su,Li-Xin Hua
DOI: https://doi.org/10.1016/j.cancergencyto.2009.09.016
2010-01-01
Cancer Genetics and Cytogenetics
Abstract:Transforming growth factor-β1 (TGFβ1) plays a significant role in regulating cellular proliferation and apoptosis. The TGFβ1 T29C polymorphism reportedly affects cancer risk, but pertinent studies offer conflicting results. We therefore performed a meta-analysis based on 40 studies from 32 publications, assessing the strength of the association using odds ratios with 95% confidence intervals. Overall, no evidence has indicated that individuals carrying CC or CT genotypes had significantly increased cancer risks, compared with TT genotype carriers [CC vs. TT: odds ratio (OR)=1.10, 95% confidence interval (95% CI)=1.00–1.21, P=0.06; CT vs. TT: OR=1.07, 95% CI=0.99–1.16, P=0.09). However, stratified analysis by cancer type and ethnicity indicated a significantly increased risk of prostate cancer (CT vs. TT: OR=1.28, 95% CI=1.01–1.61, P=0.04) and cancer in those of Asian descent (CC vs. TT: OR=1.26, 95% CI=1.03–1.53, P=0.02; CT vs. TT: OR=1.20, 95% CI=1.01–1.43, P=0.04). This association was also observed in the dominant model for prostate cancer. Although not all bias could be eliminated, this meta-analysis suggested that TGFβ1 29C was a low-penetrant risk factor for prostate cancer and cancer in Asians. A larger single study is still required to evaluate any association with other types of cancer or in other populations.